Equitable Trust Co. Purchases 98,172 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Equitable Trust Co. increased its stake in Elanco Animal Health by 65.5% in Q2, acquiring an additional 98,172 shares, bringing its total holdings to 248,108 shares valued at approximately $3.54 million.
• Elanco reported earnings of $0.26 per share for the last quarter, surpassing analyst expectations of $0.20, with a strong revenue of $1.24 billion.
• Several analysts have upgraded Elanco’s stock rating, leading to a consensus rating of "Moderate Buy" with a target price of $19.14, indicating positive market sentiment for the company.

Equitable Trust Co. boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 65.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 248,108 shares of the company's stock after purchasing an additional 98,172 shares during the quarter. Equitable Trust Co.'s holdings in Elanco Animal Health were worth $3,543,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of ELAN. Nuveen LLC bought a new stake in shares of Elanco Animal Health in the 1st quarter valued at about $115,212,000. Dimensional Fund Advisors LP increased its stake in shares of Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock valued at $214,875,000 after acquiring an additional 2,563,740 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the last quarter. ASR Vermogensbeheer N.V. bought a new stake in shares of Elanco Animal Health in the 1st quarter valued at about $23,744,000. Finally, DDD Partners LLC increased its stake in shares of Elanco Animal Health by 202.7% in the 1st quarter. DDD Partners LLC now owns 1,492,992 shares of the company's stock valued at $15,676,000 after acquiring an additional 999,716 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Trading Up 1.4%

Shares of Elanco Animal Health stock opened at $20.04 on Tuesday. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $21.76. The stock has a market cap of $9.96 billion, a P/E ratio of 23.30, a P/E/G ratio of 3.63 and a beta of 1.65. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The business's 50 day moving average is $18.47 and its 200-day moving average is $14.52.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The business had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.19 billion. During the same quarter in the prior year, the business earned $0.30 EPS. The firm's revenue for the quarter was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ELAN shares. Zacks Research raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 3rd. Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. JPMorgan Chase & Co. upgraded Elanco Animal Health from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Elanco Animal Health in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $19.14.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.